Companies: 10,795·Total market cap: $144.5T
Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc.

ERNANASDAQHealthcare● Active
$7.39
$-0.50(-6.34%)
Market Cap$2321376
P/E Ratio—
52W High$71.5
52W Low$3.18
Overview

Ernexa Therapeutics Inc. (ERNA) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ERNA · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$1.9M▲ +9.0% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$1.9M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+9.0%
vs prior fiscal year
Latest Quarter
$9.2M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$1.9MCash on Hand
Total Debt$490,000Total Debt
Net Cash / Net Debt+$1.4MNet Cash Position
Cash vs Debt Ratio
Cash 79%Debt 21%

Ernexa Therapeutics Inc. has a net cash position of $1.4M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$1.9M − $490,000 = +$1.4M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
ERNA annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$1.9M+9.0%
Dec 31, 2024$1.7M-77.2%
Dec 31, 2023$7.6M-33.8%
Dec 31, 2022$11.4M-32.6%
Dec 31, 2021$17.0M+942.0%
ERNA cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc.YOU
ERNA
$1.9M81.2%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Ernexa Therapeutics Inc. (ERNA) cash on hand as of December 31, 2025 is $1.9M, comprising $1.9M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Ernexa Therapeutics Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Ernexa Therapeutics Inc. cash reserves or cash position.

Ernexa Therapeutics Inc. annual cash on hand history shows increased +9.0% in 2025: increased +9.0% in 2025. Ernexa Therapeutics Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Ernexa Therapeutics Inc. carries total debt of $490,000 against cash of $1.9M, resulting in a net cash position of +$1.4M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

ERNA cash on hand · 5 questions

As of December 31, 2025, Ernexa Therapeutics Inc. (ERNA) has $1,884,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $1,884,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $9,177,000. Data sourced from the annual 10-K filing via FMP.

ERNA cash on handERNA cash reservesERNA cash 2025how much cash does ERNA have

▸ Source: FMP /balance-sheet-statement · US GAAP · Ernexa Therapeutics Inc. · Ernexa Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025